What is the difference between Cagrilintide and Semaglutide?

Cagrilintide is classified as: Long-acting amylin (and calcitonin) receptor agonist / amylin analogue. Semaglutide is classified as: Glucagon-like peptide-1 (GLP-1) receptor agonist. Cagrilintide is investigational and is not an approved medicine. Semaglutide is approved for one or more medical uses in at least one major jurisdiction.

Is Cagrilintide or Semaglutide approved?

Cagrilintide is investigational and is not an approved medicine. Semaglutide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Cagrilintide and Semaglutide?

Peptide Science Daily tracks 42 registered clinical trials for Cagrilintide (evidence grade B) and 500 for Semaglutide (evidence grade A).

Compound comparison

Cagrilintide vs Semaglutide

This page sets Cagrilintide and Semaglutide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Cagrilintide
Long-acting amylin (and calcitonin) receptor agonist / amylin analogue
Semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonist
Mechanism: Cagrilintide
In plain terms, cagrilintide mimics amylin, a hormone released with insulin that promotes fullness and slows digestion.
Semaglutide
In plain terms, semaglutide copies a natural gut hormone that signals fullness and helps control blood sugar.
United States (FDA): Cagrilintide
Investigational; not approved as a standalone product. As part of the CagriSema combination (with semaglutide), a new drug application has been filed and an FDA decision is expected later in 2026.
Semaglutide
Approved. Ozempic for type 2 diabetes (2017, cardiovascular risk reduction added 2020); Rybelsus oral for type 2 diabetes (2019); Wegovy for chronic weight management (2021) and cardiovascular risk reduction (2024); oral Wegovy for weight management approved in 2025.
European Union (EMA): Cagrilintide
Not authorized; investigational, no marketing authorization.
Semaglutide
Authorized - Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management.
Australia (TGA): Cagrilintide
Not entered on the ARTG; investigational only and not approved for supply.
Semaglutide
Registered on the ARTG - Ozempic for type 2 diabetes and Wegovy for weight management, available on prescription.
WADA: Cagrilintide
Not listed on the WADA Prohibited List. Amylin analogues are not banned substances; as an investigational agent it falls outside approved therapeutic use.
Semaglutide
Not prohibited. On the WADA Monitoring Program (introduced 2024, continued into 2026); it is tracked but not a banned substance.
Evidence grade: Cagrilintide
B
Semaglutide
A
Tracked clinical trials: Cagrilintide
42
Semaglutide
500
Full profile: Cagrilintide
Cagrilintide profile
Semaglutide
Semaglutide profile

Comparison of Cagrilintide and Semaglutide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Cagrilintide	Semaglutide
Class	Long-acting amylin (and calcitonin) receptor agonist / amylin analogue	Glucagon-like peptide-1 (GLP-1) receptor agonist
Mechanism	In plain terms, cagrilintide mimics amylin, a hormone released with insulin that promotes fullness and slows digestion.	In plain terms, semaglutide copies a natural gut hormone that signals fullness and helps control blood sugar.
United States (FDA)	Investigational; not approved as a standalone product. As part of the CagriSema combination (with semaglutide), a new drug application has been filed and an FDA decision is expected later in 2026.	Approved. Ozempic for type 2 diabetes (2017, cardiovascular risk reduction added 2020); Rybelsus oral for type 2 diabetes (2019); Wegovy for chronic weight management (2021) and cardiovascular risk reduction (2024); oral Wegovy for weight management approved in 2025.
European Union (EMA)	Not authorized; investigational, no marketing authorization.	Authorized - Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management.
Australia (TGA)	Not entered on the ARTG; investigational only and not approved for supply.	Registered on the ARTG - Ozempic for type 2 diabetes and Wegovy for weight management, available on prescription.
WADA	Not listed on the WADA Prohibited List. Amylin analogues are not banned substances; as an investigational agent it falls outside approved therapeutic use.	Not prohibited. On the WADA Monitoring Program (introduced 2024, continued into 2026); it is tracked but not a banned substance.
Evidence grade	B	A
Tracked clinical trials	42	500
Full profile	Cagrilintide profile	Semaglutide profile

Common questions

What is the difference between Cagrilintide and Semaglutide?: Cagrilintide is classified as: Long-acting amylin (and calcitonin) receptor agonist / amylin analogue. Semaglutide is classified as: Glucagon-like peptide-1 (GLP-1) receptor agonist. Cagrilintide is investigational and is not an approved medicine. Semaglutide is approved for one or more medical uses in at least one major jurisdiction.
Is Cagrilintide or Semaglutide approved?: Cagrilintide is investigational and is not an approved medicine. Semaglutide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Cagrilintide and Semaglutide?: Peptide Science Daily tracks 42 registered clinical trials for Cagrilintide (evidence grade B) and 500 for Semaglutide (evidence grade A).